full length recombinant human pro mmp 13 (R&D Systems)
R&D Systems is a verified supplier 
R&D Systems manufactures this product 
94
Structured Review
R&D Systems
full length recombinant human pro mmp 13
Full Length Recombinant Human Pro Mmp 13, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 42 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/full+length+recombinant+human+pro+mmp+13/Recombinant+Human+MMP-13+Protein%2C+CF/pmc04255739-181-0-8
Average 94 stars, based on 42 article reviews
Full Length Recombinant Human Pro Mmp 13, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 42 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/full+length+recombinant+human+pro+mmp+13/Recombinant+Human+MMP-13+Protein%2C+CF/pmc04255739-181-0-8
Average 94 stars, based on 42 article reviews
full length recombinant human pro mmp 13 - by Bioz Stars,
2026-10
94/100 stars
Images
Related Articles
Recombinant:Article Title: Characterization of Selective Exosite-Binding Inhibitors of Matrix Metalloproteinase 13 That Prevent Articular Cartilage Degradation in Vitro Article Snippet: .. Article Title: Characterization of Selective Exosite-Binding Inhibitors of Matrix Metalloproteinase 13 That Prevent Articular Cartilage Degradation in Vitro Article Snippet: ■ EXPERIMENTAL PROCEDURES MMP-13 inhibitors were synthesized and characterized as described elsewhere.32 [(Pyrimidine-4,6-dicarboxylic acid bis(4-fluoro-3-methylbenzamide)] was obtained from EMD Biosciences/Calbiochem (product no. 444283; San Diego, CA). .. The synthesis, purification, and characterization of the fluorogenic triple-helical peptide substrate (fTHP-15) have been described.57 Purification:Article Title: Characterization of Selective Exosite-Binding Inhibitors of Matrix Metalloproteinase 13 That Prevent Articular Cartilage Degradation in Vitro Article Snippet: ■ EXPERIMENTAL PROCEDURES MMP-13 inhibitors were synthesized and characterized as described elsewhere.32 [(Pyrimidine-4,6-dicarboxylic acid bis(4-fluoro-3-methylbenzamide)] was obtained from EMD Biosciences/Calbiochem (product no. 444283; San Diego, CA). .. The synthesis, purification, and characterization of the fluorogenic triple-helical peptide substrate (fTHP-15) have been described.57 |